SCHEDULE 13G/A: Perceptive Advisors Discloses 6.1% Passive Stake in Edgewise Therapeutics
Beneficial Ownership Disclosure
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have jointly reported a 6.1% passive beneficial ownership stake in Edgewise Therapeutics, Inc.
Summary
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Edgewise Therapeutics, Inc.
- The Reporting Persons collectively beneficially own 6,395,546 shares of Edgewise Therapeutics, Inc. Common Stock.
- This ownership represents 6.1% of the Issuer's outstanding Common Stock.
- The percentage is calculated based on 105,200,221 shares of Common Stock outstanding as of March 31, 2025, as reported in Edgewise Therapeutics' Quarterly Report on Form 10-Q filed on May 8, 2025.
- Perceptive Life Sciences Master Fund, Ltd. directly holds all 6,395,546 shares.
- Perceptive Advisors LLC serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors LLC, granting them shared voting and dispositive power over the shares.
- The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, indicating a passive investment intent.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing disclosing a significant passive ownership stake by a specialized investment firm. While it doesn't contain new operational or financial performance data, the presence of a notable investor can be interpreted as a neutral to slightly positive signal of investor interest.
Positives
- A significant stake (6.1%) in Edgewise Therapeutics, Inc. has been disclosed by Perceptive Advisors LLC and its affiliates, a prominent investment firm specializing in life sciences, which can be interpreted as a signal of investor interest in the company.
Future Outlook
This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding Edgewise Therapeutics, Inc.'s future operations or financial performance.
Management Comments
- Joseph Edelman, Managing Member of Perceptive Advisors LLC, certified that, to the best of his knowledge and belief, the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.
Industry Context
Perceptive Advisors LLC is a well-known investment firm with a strong focus on the life sciences sector. Their disclosed passive investment in Edgewise Therapeutics, a biotechnology company, aligns with their established investment strategy and specialization within the industry.
Stakeholder Impact
- Shareholders: The disclosure of a significant passive stake by a specialized investment firm like Perceptive Advisors may provide a degree of confidence or stability regarding the company's investor base.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which required the filing of this statement (the date the beneficial ownership threshold was met or exceeded). |
| 05/08/2025 | Date Edgewise Therapeutics, Inc. filed its Quarterly Report on Form 10-Q, reporting 105,200,221 shares of Common Stock outstanding, which was used for the ownership percentage calculation. |
| 05/15/2025 | Date of filing and signature of this Schedule 13G Amendment No. 1. |
Keywords
Edgewise Therapeutics, Perceptive Advisors, Joseph Edelman, Schedule 13G, Common Stock, Beneficial Ownership, Passive Investment, Biotechnology, Life Sciences
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.